255 related articles for article (PubMed ID: 31503397)
21. Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis.
Groot Koerkamp B; Sadot E; Kemeny NE; Gönen M; Leal JN; Allen PJ; Cercek A; DeMatteo RP; Kingham TP; Jarnagin WR; D'Angelica MI
J Clin Oncol; 2017 Jun; 35(17):1938-1944. PubMed ID: 28426374
[TBL] [Abstract][Full Text] [Related]
22. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
[TBL] [Abstract][Full Text] [Related]
23. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
House MG; Kemeny NE; Gönen M; Fong Y; Allen PJ; Paty PB; DeMatteo RP; Blumgart LH; Jarnagin WR; D'Angelica MI
Ann Surg; 2011 Dec; 254(6):851-6. PubMed ID: 21975318
[TBL] [Abstract][Full Text] [Related]
24. Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program.
Walker BS; Billingsley KG; Sutton TL; Kolbeck KJ; Korngold EK; Nabavizadeh N; Dewey EN; Herzig DO; Lopez CD; Mayo SC
J Surg Oncol; 2022 Sep; 126(3):513-522. PubMed ID: 35522249
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer.
Furuki H; Yamada T; Takahashi G; Iwai T; Koizumi M; Shinji S; Yokoyama Y; Takeda K; Taniai N; Uchida E
Eur J Surg Oncol; 2018 Jul; 44(7):975-982. PubMed ID: 29452859
[TBL] [Abstract][Full Text] [Related]
26. Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy.
Sebagh M; Allard MA; Bosselut N; Dao M; Vibert E; Lewin M; Lemoine A; Cherqui D; Adam R; Sa Cunha A
Oncotarget; 2016 Apr; 7(16):21591-600. PubMed ID: 26943031
[TBL] [Abstract][Full Text] [Related]
27. RAS/TP53 Co-mutation is Associated With Worse Survival After Concurrent Resection of Colorectal Liver Metastases and Extrahepatic Disease.
Lillemoe HA; Passot G; Kawaguchi Y; DeBellis M; Glehen O; Chun YS; Tzeng CD; Aloia TA; Lopez J; Vauthey JN
Ann Surg; 2022 Aug; 276(2):357-362. PubMed ID: 33351476
[TBL] [Abstract][Full Text] [Related]
28. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.
Link KH; Pillasch J; Formentini A; Sunelaitis E; Leder G; Safi F; Kornmann M; Beger HG
Eur J Surg Oncol; 1999 Aug; 25(4):381-8. PubMed ID: 10419708
[TBL] [Abstract][Full Text] [Related]
29. Meeting the biologic challenge of colorectal metastases.
Wanebo HJ; LeGolvan M; Paty PB; Saha S; Zuber M; D'Angelica MI; Kemeny NE
Clin Exp Metastasis; 2012 Oct; 29(7):821-39. PubMed ID: 23053740
[TBL] [Abstract][Full Text] [Related]
30. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
31. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.
Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN
J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911
[TBL] [Abstract][Full Text] [Related]
32. Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases.
Lang H; Baumgart J; Heinrich S; Tripke V; Passalaqua M; Maderer A; Galle PR; Roth W; Kloth M; Moehler M
Ann Surg; 2019 Nov; 270(5):799-805. PubMed ID: 31634180
[TBL] [Abstract][Full Text] [Related]
33. The state of hepatic artery infusion chemotherapy in the management of metastatic colorectal cancer to the liver.
Leung M; Gholami S
Chin Clin Oncol; 2019 Oct; 8(5):54. PubMed ID: 31597435
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of Hepatic Artery Infusion (HAI) Versus Selective Internal Radiation Therapy (Y90) for Pretreated Isolated Unresectable Colorectal Liver Metastases (IU-CRCLM).
Dhir M; Zenati MS; Jones HL; Bartlett DL; Choudry MHA; Pingpank JF; Holtzman MP; Bahary N; Hogg ME; Zeh HJ; Geller DA; Wallis Marsh J; Tsung A; Zureikat AH
Ann Surg Oncol; 2018 Feb; 25(2):550-557. PubMed ID: 29181682
[TBL] [Abstract][Full Text] [Related]
36. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
37. Limitations of molecular biomarkers in patients with resectable colorectal liver metastases.
Brudvik KW; Shindoh J
Chin Clin Oncol; 2019 Oct; 8(5):48. PubMed ID: 31500431
[TBL] [Abstract][Full Text] [Related]
38. Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study.
Guadagni S; Clementi M; Mackay AR; Ricevuto E; Fiorentini G; Sarti D; Palumbo P; Apostolou P; Papasotiriou I; Masedu F; Valenti M; Giordano AV; Bruera G
J Cancer Res Clin Oncol; 2020 May; 146(5):1273-1290. PubMed ID: 32088781
[TBL] [Abstract][Full Text] [Related]
39. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
40. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
